Pluri Inc. reported its financial results for the nine-month period ending March 31, 2026, revealing a decline in revenue and an increase in net losses compared to the previous fiscal year. The company generated revenues of $681,000 for the nine months, down from $938,000 in the same period last year. For the three-month period ending March 31, 2026, revenues were $167,000, compared to $427,000 in the prior year. The decrease in revenue was attributed to a lower volume of project activity, particularly in the Contract Development and Manufacturing Organization (CDMO) sector and AgTech collaborations.
The company's net loss for the nine-month period was $19.2 million, an increase from a loss of $15.5 million in the same period last year. For the three-month period, the net loss was $6.2 million, slightly down from $6.3 million in the previous year. The increase in net loss was primarily driven by higher research and development (R&D) expenses, which rose by 32% to $11.7 million, largely due to increased salaries and related expenses following the acquisition of Kokomodo, as well as higher lease expenses and share-based compensation.
In terms of strategic developments, Pluri Inc. has made significant organizational changes, including the acquisition of approximately 79% of Kokomodo, an innovative agfood startup focused on sustainable cacao production. The company also launched its PluriCDMO™ division in January 2024, which has begun generating revenue through agreements with clients. Additionally, Pluri has entered into various collaborations across its subsidiaries, including Coffeesai and Ever After Foods, to explore applications of its proprietary technologies in cultivated meat, cacao, and coffee.
Operationally, Pluri's employee headcount has increased due to the acquisition of Kokomodo, although specific figures were not disclosed. The company reported a total of 268,878 share options outstanding as of March 31, 2026, with a weighted average exercise price of $13.62. The company also granted 129,082 restricted stock units (RSUs) during the nine-month period, with 344,559 RSUs remaining unvested at the end of the period. The company’s cash and cash equivalents totaled $9.5 million as of March 31, 2026, down from $26.7 million a year earlier, indicating a need for additional liquidity to support ongoing operations.
Looking ahead, Pluri Inc. anticipates challenges in generating significant revenues from product sales in the next twelve months and may need to secure additional funding to support its commercialization efforts and R&D activities. The company has acknowledged that its current cash resources may only cover operating obligations for less than three months, raising concerns about its ability to continue as a going concern. The management is focused on implementing cost-saving initiatives and exploring various funding sources, including potential restructuring of its existing loans and seeking non-dilutive grants.
About Pluri Inc.
Pluri Inc. is a biotechnology company specializing in proprietary 3D cell expansion technology for scalable solutions across healthcare, food, and agriculture. Its core activities include developing cell therapies, regenerative medicine, cultivated food products, and contract manufacturing services. The company leverages its innovative platform for cell-based therapeutics, food tech, and AgTech, serving global markets with a focus on sustainability, cost-efficiency, and advanced bioprocessing.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.